|
Ovarian Cancer – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 418 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'Ovarian Cancer - Pipeline Review, H1 2012', provides an overview of the Ovarian Cancer therapeutic pipeline. This report provides information on the therapeutic.....
Introduction Global Markets Direct’s, 'Ovarian Cancer - Pipeline Review, H1 2012', provides an overview of the Ovarian Cancer therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. 'Ovarian Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Ovarian Cancer. - A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ovarian Cancer pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Ovarian Cancer therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 13 Introduction 14 Global Markets Direct Report Coverage 14 Ovarian Cancer Overview 15 Therapeutics Development 16 An Overview of Pipeline Products for Ovarian Cancer 16 Ovarian Cancer Therapeutics under Development by Companies 18 Ovarian Cancer Therapeutics under Investigation by Universities/Institutes 28 Late Stage Products 39 Comparative Analysis 39 Mid Clinical Stage Products 40 Comparative Analysis 40 Early Clinical Stage Products 41 Comparative Analysis 41 Discovery and Pre-Clinical Stage Products 42 Comparative Analysis 42 Ovarian Cancer Therapeutics – Products under Development by Companies 43 Ovarian Cancer Therapeutics – Products under Investigation by Universities/Institutes 58 Companies Involved in Ovarian Cancer Therapeutics Development 89 Johnson & Johnson 89 Boehringer Ingelheim GmbH 90 F. Hoffmann-La Roche Ltd. 91 Abbott Laboratories 92 Amgen Inc. 93 Sanofi-Aventis 94 AstraZeneca PLC 95 Eli Lilly and Company 96 Viralytics Ltd. 97 GlaxoSmithKline plc 98 Tekmira Pharmaceuticals Corp. 99 Genentech, Inc. 100 Nektar Therapeutics 101 Daiichi Sankyo Company, Ltd 102 Merck & Co., Inc. 103 Micromet, Inc. 104 Generex Biotechnology Corporation 105 Takeda Pharmaceutical Company Limited 106 Bio-Path Holdings, Inc. 107 Millennium Pharmaceuticals, Inc. 108 Novartis AG 109 Viventia Biotechnologies Inc. 198 TRACON Pharmaceuticals, Inc. 199 Advanced Cancer Therapeutics 200 Oncolix, Inc. 201 OHR Pharmaceutical Inc. 202 RECEPTA Biopharma S.A. 203 Kyowa Hakko Kirin Pharma, Inc. 204 Vaxonco 205 Sentinel Oncology Limited 206 Mebiopharm Co., Ltd. 207 VectorLogics, Inc. 208 ISA Pharmaceuticals B.V. 209 Gradalis Inc. 210 Oncozyme Pharma Inc. 211 Ovarian Cancer – Therapeutics Assessment 212 Assessment by Monotherapy Products 212 Assessment by Combination Products 213 Assessment by Route of Administration 214 Assessment by Molecule Type 217 Drug Profiles 220 AMG 386 - Drug Profile 220 Abagovomab - Drug Profile 222 OPAXIO - Drug Profile 223 MORAb-003 - Drug Profile 225 Paclical - Drug Profile 227 Telcyta - Drug Profile 229 NV06 - Drug Profile 231 Vargatef - Drug Profile 232 Tirazone - Drug Profile 234 Particulate Delivery - Drug Profile 235 Trabectedin - Drug Profile 236 Carboplatin + Thalidomide - Drug Profile 237 Amifostine Trihydrate - Drug Profile 238 Phenoxodiol + Carboplatin - Drug Profile 239 Bevacizumab + Carboplatin + Gemcitabine - Drug Profile 240 Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 242 Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 244 Oxaliplatin + Capecitabine + Bevacizumab - Drug Profile 246 Carboplatin + Taxol - Drug Profile 248 Cisplatin + Taxol - Drug Profile 249 Carboplatin + Gemcitabine + Paclitaxel - Drug Profile 250 Carboplatin + Paclitaxel - Drug Profile 252 Paclitaxel + Carboplatin + Topotecan - Drug Profile 255 Carboplatin + Ifosfamide - Drug Profile 257 Carboplatin + Ifosfamide + Whole Body Hyperthermia - Drug Profile 259 Carboplatin + Paclitaxel + Cediranib - Drug Profile 261 Carboplatin + Paclitaxel + Doxorubicin HCl Liposome - Drug Profile 263 Carboplatin + Paclitaxel + Gemcitabine - Drug Profile 265 Carboplatin + Topotecan Hydrochloride - Drug Profile 267 Carboplatin + Gemcitabine - Drug Profile 269 Carboplatin + Paclitaxel - Drug Profile 271 Carboplatin - Drug Profile 273 Bevacizumab + Carboplatin + Docetaxel + Paclitaxel - Drug Profile 274 Sodium Thiosulfate - Drug Profile 275 Paclitaxel - Drug Profile 276 Taxol + Paraplatin - Drug Profile 277 AMG 386 + Pegylated Liposomal Doxorubicin - Drug Profile 279 AMG 386 + Paclitaxel - Drug Profile 280 Carboplatin + Paclitaxel - Drug Profile 281 Treosulfan - Drug Profile 283 Carboplatin + Gemcitabine Hydrochloride + Paclitaxel - Drug Profile 284 Carboplatin + Liposomal Doxorubicin - Drug Profile 286 Ifosfamide + Paclitaxel - Drug Profile 287 Yondelis + DOXIL - Drug Profile 289 Avastin + Carboplatin + Paclitaxel - Drug Profile 290 Avastin + Carboplatin + Paclitaxel - Drug Profile 292 Avastin + Paclitaxel + Topotecan + Liposomal Doxorubicin - Drug Profile 294 Gemcitabine + Carboplatin - Drug Profile 295 Telcyta + Paraplatin - Drug Profile 297 Topotecan - Drug Profile 299 Karenitecin - Drug Profile 300 CAELYX + Carboplatin - Drug Profile 301 Paclitaxel + Carboplatin - Drug Profile 302 Doxorubicin + Carboplatin + Paclitaxel - Drug Profile 303 Cisplatin - Drug Profile 305 Cyclophosphamide + Cisplatin - Drug Profile 306 Bevacizumab + Cisplatin + Paclitaxel - Drug Profile 307 EC145 + Doxil - Drug Profile 309 Cisplatin - Drug Profile 310 Cisplatin + Carboplatin - Drug Profile 311 Avastin - Drug Profile 313 Filgrastim + Doxorubicin + Ifosfamide - Drug Profile 314 Doxorubicin + Carboplatin - Drug Profile 316 Paclitaxel + Carboplatin - Drug Profile 317 Docetaxel + Carboplatin - Drug Profile 318 Paclitaxel + Carboplatin - Drug Profile 319 Oxaliplatin + Capecitabine - Drug Profile 320 Carboplatin + Taxol - Drug Profile 321 Irinotecan + Cisplatin - Drug Profile 323 Irinotecan + Cisplatin - Drug Profile 325 Taxol + Paraplatin + Bevacizumab - Drug Profile 326 cediranib - Drug Profile 328 Paclitaxel + Carboplatin + Epirubicin - Drug Profile 329 Irinotecan + Cisplatin - Drug Profile 331 Votrient - Drug Profile 332 Tarceva - Drug Profile 334 Paclitaxel + AZD0530 - Drug Profile 336 Cisplatin + Cyclophosphamide + Tamoxifen - Drug Profile 337 Bevacizumab + Carboplatin + Paclitaxel - Drug Profile 339 Carboplatin + Pegylated Liposomal Doxorubicin - Drug Profile 341 OPT-821 + Polyvalent Antigen-KLH Conjugate Vaccine - Drug Profile 342 Cisplatin + Topotecan + Paclitaxel + Carboplatin - Drug Profile 344 Carboplatin + Pegylated Liposomal Doxorubicin - Drug Profile 346 Carboplatin + Glutathione + Paclitaxel - Drug Profile 347 bevacizumab + capecitabine + carboplatin + oxaliplatin + paclitaxel - Drug Profile 349 Carboplatin + Paclitaxel + Bevacizumab - Drug Profile 352 Cisplatin + Paclitaxel - Drug Profile 354 CT-2103 - Drug Profile 355 Cisplatin + Taxol - Drug Profile 357 Cisplatin + Adriamycin - Drug Profile 358 Pegylated Liposomal Doxorubicin + Trabectedin - Drug Profile 359 Ovarian Cancer Therapeutics – Drug Profile Updates 360 Ovarian Cancer Therapeutics – Discontinued Products 368 Ovarian Cancer Therapeutics - Dormant Products 374 Ovarian Cancer – Product Development Milestones 401 Featured News & Press Releases 401 Appendix 410 Methodology 410 Expert Panel Validation 411 Contact Us 411 Disclaimer 411 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for Ovarian Cancer, H1 2012 23 Products under Development for Ovarian Cancer – Comparative Analysis, H1 2012 24 Number of Products under Development by Companies, H1 2012 26 Number of Products under Investigation by Universities/Institutes, H1 2012 36 Comparative Analysis by Late Stage Development, H1 2012 46 Comparative Analysis by Mid Clinical Stage Development, H1 2012 47 Comparative Analysis by Early Clinical Stage Development, H1 2012 48 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 49 Products under Development by Companies, H1 2012 50 Products under Investigation by Universities/Institutes, H1 2012 65 Johnson & Johnson, H1 2012 96 Boehringer Ingelheim GmbH, H1 2012 97 F. Hoffmann-La Roche Ltd., H1 2012 98 Abbott Laboratories, H1 2012 99 Amgen Inc., H1 2012 100 Sanofi-Aventis, H1 2012 101 AstraZeneca PLC, H1 2012 102 Eli Lilly and Company, H1 2012 103 Viralytics Ltd., H1 2012 104 GlaxoSmithKline plc, H1 2012 105 Tekmira Pharmaceuticals Corp., H1 2012 106 Genentech, Inc., H1 2012 107 Nektar Therapeutics, H1 2012 108 Daiichi Sankyo Company, Ltd, H1 2012 109 Merck & Co., Inc., H1 2012 110 Micromet, Inc., H1 2012 111 Generex Biotechnology Corporation, H1 2012 112 Takeda Pharmaceutical Company Limited, H1 2012 113 Bio-Path Holdings, Inc., H1 2012 114 Millennium Pharmaceuticals, Inc., H1 2012 115 Novartis AG, H1 2012 116 Samyang Corporation, H1 2012 117 Aphios Corporation, H1 2012 118 ImClone Systems Incorporated, H1 2012 119 Eisai Co., Ltd., H1 2012 120 ImmunoGen, Inc., H1 2012 121 OSI Pharmaceuticals, Inc., H1 2012 122 Cell Therapeutics, Inc., H1 2012 123 Santaris Pharma A/S, H1 2012 124 Exelixis, Inc., H1 2012 125 Aduro BioTech, H1 2012 126 TopoTarget A/S, H1 2012 151 Karolinska Institutet, H1 2012 152 Poniard Pharmaceuticals, Inc., H1 2012 153 Oncogenex Pharmaceuticals, Inc., H1 2012 154 Dendreon Corporation, H1 2012 155 Thallion Pharmaceuticals Inc., H1 2012 156 Prima BioMed Limited, H1 2012 157 PharmaGap Inc., H1 2012 158 Quest PharmaTech Inc., H1 2012 159 Synta Pharmaceuticals Corp., H1 2012 160 Oasmia Pharmaceutical AB, H1 2012 161 Algeta ASA, H1 2012 162 RXi Pharmaceuticals Corporation, H1 2012 163 Rexahn Pharmaceuticals, Inc., H1 2012 164 MabVax Therapeutics, Inc., H1 2012 165 Morphotek, Inc., H1 2012 166 Oryzon, H1 2012 167 GANYMED Pharmaceuticals AG, H1 2012 168 Abiogen Pharma S.p.A., H1 2012 169 Glycotope GmbH, H1 2012 170 BioNumerik Pharmaceuticals, Inc., H1 2012 171 Indena S.p.A., H1 2012 172 Alethia Biotherapeutics Inc., H1 2012 173 Coronado Biosciences, Inc., H1 2012 174 Heat Biologics, Inc., H1 2012 175 MacroGenics, Inc., H1 2012 176 Fresenius Biotech GmbH, H1 2012 177 Azaya Therapeutics, Inc., H1 2012 178 CanBas Co., Ltd., H1 2012 179 Merrimack Pharmaceuticals, Inc., H1 2012 180 Spirogen Ltd., H1 2012 181 Neotropix, Inc., H1 2012 182 Conatus Pharmaceuticals Inc., H1 2012 183 CritiTech, Inc., H1 2012 184 BioCancell Therapeutics, Inc., H1 2012 185 Endocyte, Inc., H1 2012 186 Advenchen Laboratories, LLC, H1 2012 187 Onconova Therapeutics, Inc, H1 2012 188 MolMed S.p.A., H1 2012 189 Immunotope, Inc., H1 2012 190 Esperance Pharmaceuticals, Inc., H1 2012 191 Bolder Biotechnology, Inc., H1 2012 192 BiPar Sciences, Inc., H1 2012 193 ImmunoVaccine Technologies Inc., H1 2012 194 Welichem Biotech Inc., H1 2012 195 Angstrom Pharmaceuticals, Inc., H1 2012 196 Vaccinogen, Inc., H1 2012 197 Cancer Vaccines Limited, H1 2012 198 NewLink Genetics Corporation, H1 2012 199 TVAX Biomedical, LLC, H1 2012 200 Quintessence Biosciences, Inc., H1 2012 201 arGEN-X BV, H1 2012 202 Kinex Pharmaceuticals, LLC, H1 2012 203 Tigris Pharmaceuticals, Inc., H1 2012 204 Viventia Biotechnologies Inc., H1 2012 205 TRACON Pharmaceuticals, Inc., H1 2012 206 Advanced Cancer Therapeutics, H1 2012 207 Oncolix, Inc., H1 2012 208 OHR Pharmaceutical Inc., H1 2012 209 RECEPTA Biopharma S.A., H1 2012 210 Kyowa Hakko Kirin Pharma, Inc., H1 2012 211 Vaxonco, H1 2012 212 Sentinel Oncology Limited, H1 2012 213 Mebiopharm Co., Ltd., H1 2012 214 VectorLogics, Inc., H1 2012 215 ISA Pharmaceuticals B.V., H1 2012 216 Gradalis Inc., H1 2012 217 Oncozyme Pharma Inc., H1 2012 218 Assessment by Monotherapy Products, H1 2012 219 Assessment by Combination Products, H1 2012 220 Assessment by Stage and Route of Administration, H1 2012 223 Assessment by Molecule Type, H1 2012 226 Ovarian Cancer Therapeutics – Drug Profile Updates 367 Ovarian Cancer Therapeutics – Discontinued Products 375 Ovarian Cancer Therapeutics – Dormant Products 381 List of Figures Number of Products under Development for Ovarian Cancer, H1 2012 23 Products under Development for Ovarian Cancer – Comparative Analysis, H1 2012 24 Products under Development by Companies, H1 2012 25 Products under Investigation by Universities/Institutes, H1 2012 35 Late Stage Products, H1 2012 46 Mid Clinical Stage Products, H1 2012 47 Early Clinical Stage Products, H1 2012 48 Discovery and Pre-Clinical Stage Products, H1 2012 49 Assessment by Monotherapy Products, H1 2012 219 Assessment by Combination Products, H1 2012 220 Assessment by Route of Administration, H1 2012 221 Assessment by Stage and Route of Administration, H1 2012 222 Assessment by Molecule Type, H1 2012 224 Assessment by Stage and Molecule Type, H1 2012 225 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
